Abstract:atresia.However, utility of HIDA scan in preterm neonates is not well-established.Herein, we aim to (1) review the etiologies of neonatal cholestasis among term and preterm neonates with cholestasis, (2) identify clinical variables associated with a diagnosis of BA and non-BA and (3) investigate the utility of HIDA in predicting BA among preterm neonates.Methods: Retrospective cohort study of neonates born and investigated for neonatal cholestasis at 2 co-located neonatal and children facilities from January 2013 to December 2017.Demographic, clinical, laboratory variables and ultrasound features were collected to identify for variables associated with diagnosis of BA and non-BA via univariable and multivariable analysis.Sensitivity of specificity of HIDA in predicting BA were calculated for term and preterm neonates.Results: 139 neonates with cholestasis were identified (40 term; 99 preterm), of which 28 term and 24 preterm underwent HIDA investigation.Among the term neonates, the etiologies of cholestasis were BA (18%), intestinal failure related liver disease (IFALD) (13%), cytomegalovirus (1%), idiopathic neonatal hepatitis (1%).Among the preterm neonates, these proportions were IFALD (66%), CMV/sepsis related (5%), BA (2%), cystic fibrosis (2%).Incidence of BA among neonatal cholestasis was higher in term(1:6) than preterm(1:50) cohorts.(OR 10.29; 95% CI 2.06-49.97,P=0.0024) Variables significantly associated with BA on univariable regression analysis were: higher birth weight(OR P=0.002), presence of acholic stool(P=0.002),absent gallbladder(P=0.003)or abnormal gallbladder morphology(P=0.024).Variables significantly associated with non-BA on multivariable regression analysis were gestational age ≤32 weeks(P=0.046),total parenteral nutrition ≥14 days(P=0.009).In predicting BA, non-draining HIDA demonstrated a lower specificity (73% vs 90%) and lower PPV (25% vs 78%) in preterm compared to term neonates.Conclusions: Etiologies of cholestasis among preterm neonates differ from those in term neonates and neonatal cholestasis in preterm may not warrant extensive evaluations for exclusion for BA, given the lower prevalence of BA and lower utility of HIDA among preterm neonates.Preexisting diagnostic approach to neonatal cholestasis should be modified for preterm cohort, taking into accounts of the prevalence for each etiology, potential predictors and cost-efficiency.

Identification of the Plasma Metabolomics As Early Diagnostic Markers Between Biliary Atresia and Neonatal Hepatitis Syndrome

Metabonomics Reveals Metabolite Changes in Biliary Atresia Infants

Biliary atresia and cholestasis plasma non-targeted metabolomics unravels perturbed metabolic pathways and unveils a diagnostic model for biliary atresia

Distinct Plasma Bile Acid Profiles of Biliary Atresia and Neonatal Hepatitis Syndrome

Targeted Metabolomics Reveals Birth Screening Biomarkers for Biliary Atresia in Dried Blood Spots

A Serum Metabolomic Analysis for Diagnosis and Biomarker Discovery of Primary Biliary Cirrhosis and Autoimmune Hepatitis.

Accurate Prediction of Biliary Atresia with an Integrated Model Using MMP-7 Levels and Bile Acids.

Progress in Biomarkers Related to Biliary Atresia

Elevated Bile Acids In Newborns With Biliary Atresia (Ba)

Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B

Metabolic regulation of cholestatic liver injury by D-2-hydroxyglutarate with the modulation of hepatic microenvironment and the mammalian target of rapamycin signaling

Neonatal Dubin-Johnson Syndrome and Its Differentiation from Biliary Atresia

Serum metabolic profiling of targeted bile acids reveals potentially novel biomarkers for primary biliary cholangitis and autoimmune hepatitis

High performance liquid chromatography-mass spectrometry for metabonomics: potential biomarkers for acute deterioration of liver function in chronic hepatitis B.

Serum Protein Markers Far Biliary Atresia

A serum metabonomic study on the difference between alcohol- and HBV-induced liver cirrhosis by ultraperformance liquid chromatography coupled to mass spectrometry plus quadrupole time-of-flight mass spectrometry.

Targeted LC-MS/MS Profiling of Bile Acids Reveals Primary/secondary Bile Acid Ratio As a Novel Biomarker for Necrotizing Enterocolitis.

Discovery and validation of potential serum biomarkers for pediatric patients with congenital heart diseases by metabolomics.

Mo1491 – Novel Preoperative Nomograms Predict Microvascular Invasion and Lymph Node Metastasis in Hepatocellular Carcinoma

Comprehensive Analysis of Gut Microbiota and Fecal Bile Acid Profiles in Children With Biliary Atresia

Diagnostic Values of Plasma Matrix Metalloproteinase-7, Interleukin-8, and Gamma-Glutamyl Transferase in Biliary Atresia